Alzheimer’s disease: top five clinical trials to watch out for this year

Written by Jolie Neill (Future Science Group)

Alzheimer's clinical trials

Alzheimer’s disease is the most common form of dementia accounting for 60-70% of cases. Current treatments can temporarily improve symptoms but cannot stop or reverse disease progression. Here we look at five clinical trials from the past year that show promise for the treatment of Alzheimer’s disease. ADAMANT: Phase II study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease Accumulation of abnormal Tau protein underlies the clinical decline seen in Alzheimer’s disease. The AADvac1 vaccine has the potential to slow and possibly halt the progression of tau pathology in Alzheimer’s. This 24-month randomized, placebo-controlled Phase II study...

To view this content, please register now for access

It's completely free